本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

諾和諾德

56.66
-0.8400-1.46%
盤後56.62-0.0400-0.07%19:59 EDT
成交量:763.27萬
成交額:4.31億
市值:2,515.17億
市盈率:14.42
高:56.87
開:56.28
低:55.80
收:57.50
52周最高:120.47
52周最低:45.05
股本:44.39億
流通股本:31.88億
量比:0.73
換手率:0.24%
股息:1.73
股息率:3.05%
每股收益(TTM):3.93
每股收益(LYR):3.15
淨資產收益率:79.17%
總資產收益率:21.82%
市淨率:10.17
市盈率(LYR):18.00

資料載入中...

公司資料

公司名字:
諾和諾德
交易所:
NYSE
成立時間:
1923
員工人數:
78387
公司地址:
Novo Alle 1,Bagsvaerd,Capital Region of Denmark,Denmark
郵編:
2880
傳真:
- -
簡介:
Novo Nordisk A/S成立於1989年,由兩家丹麥公司Nordisk Gentofte A/S和Novo Industri A/S合併而成。該公司是一家全球醫療保健公司,也是糖尿病和肥胖症護理領域的全球領導者。該公司擁有廣泛的糖尿病和肥胖症護理以及罕見疾病產品組合,包括用於治療糖尿病和肥胖症的胰高血糖素樣肽-1(GLP-1)受體激動劑、現代胰島素和人胰島素。

董事

名稱
職位
Helge Lund
Chairman of the Board
Henrik Poulsen
Vice Chairman of the Board
Andreas Fibig
Independent Director
Christina Law
Independent Director
Laurence Debroux
Independent Director
Martin Mackay
Independent Director
Sylvie Gregoire
Independent Director
Elisabeth Dahl Christensen
Director
Kasim Kutay
Director
Liselotte Hyveled
Director
Mette Bojer Jensen
Director
Thomas Rantzau
Director

股東

名稱
職位
Maziar Mike Doustdar
President, Chief Executive Officer
Karsten Munk Knudsen
Executive Vice President and Chief Financial Officer
Camilla Sylvest
Executive Vice President, Commercial Strategy and Corporate Affairs
David Moore
Executive Vice President, US Operations and Business Development
Henrik Wulff
Executive Vice President, Product Supply, Quality Assurance, Digital Data and Information Technology
Lars Fruergaard Jorgensen
Vice President, International Operations
Ludovic Helfgott
Executive Vice President, Rare Disease
Martin Holst Lange
Chief Scientific Officer
Tania Sabroe
Executive Vice President, People and Organisation